首页
登录
职称英语
Under existing law, a new drug may be labeled, promoted, and advertised only f
Under existing law, a new drug may be labeled, promoted, and advertised only f
游客
2024-12-31
26
管理
问题
Under existing law, a new drug may be labeled, promoted, and advertised only for those conditions in which safety and effectiveness have been demonstrated and of which the Food and Drug Administration (FDA) has approved, or socalled "approved uses." Other uses have come to be called "unapproved uses" and cannot be legally promoted. In a real sense, the term "unapproved" is a misnomer because it includes in one phrase two categories of marketed drugs that are very different; drugs which are potentially harmful and will never be approved, and already approved drugs that have "unapproved" uses. It is common for new research and new insights to demonstrate valid new uses for drugs already on the market. Also, there arc numerous examples of medical progress resulting from the serendipitous observations and therapeutic innovations of physicians, both important methods of discovery in the field of therapeutics. Before such advances can result in new indications for inclusion in drug labeling, however, the available data must meet the legal standard of substantial evidence derived from adequate and well-controlled clinical trials. Such evidence may require time to develop, and, without initiative on the part of the drug firm, it may not occur at all for certain uses. However, because medical literature on new uses exists and these uses arc medically beneficial, physicians often use these drugs for such purposes prior to FDA review or changes in labeling. This is referred to as "unlabeled uses" of drugs.
A different problem arises when a particular use for a drug has been examined scientifically and has been found to be ineffective or unsafe, and yet physicians who either are uninformed or who refuse to accept the available scientific evidence continue to use the drug in this way. Such use may have been reviewed by the FDA and rejected, or, in some cases, the use may actually be warned against in the labeling. This subset of uses may be properly termed "disapproved uses."
Government policy should minimize the extent of unlabeled uses. If such uses are valid—and many are—it is important that scientifically sound evidence supporting them be generated and that the regulatory system accommodate them into drug labeling. Continuing rapid advances in medical care and the complexity of drug usage, however, makes it impossible for the government to keep drug labeling up to date for every conceivable situation. Thus, when a particular use of this type appears, it is also important, and in the interest of good medical cure, that no stigma be attached to "unapproved usage" by practitioners while the formal evidence is assembled between the time of discovery and the time the new use is included in the labeling. In the case of "disapproved uses," however, it is proper policy to warn against these in the package insert, whether use of a drug for these purposes by the uninformed or intransigent physician constitutes a violation of the current Federal Food, Drug and Cosmetic Act is a matter of debate that involves a number of technical and legal issues. Regardless of that, the inclusion of disapproved uses in the form of contraindications, warnings and other precautionary statements in package inserts is an important practical deterrent to improper use. Except for clearly disapproved uses, however, it is in the best interests of patient care that physicians not be constrained by regulatory statutes from exercising their best judgment in prescribing a chug for both its approved uses and any unlabeled uses it may have. [br] According to the passage, an unlabeled use of a drug is any use which ______.
选项
A、has been reviewed by the FDA and specifically rejected
B、has medical value but has not yet been approved by FDA for inclusion as a labeled use
C、is authorized by the label as approved by the FDA on the basis of scientific studies
D、is made in experiments designed to determine whether a drug is medically beneficial
答案
C
解析
细节判断题。在文章第一段中,unlabeled use指任何已被FDA批准使用的药品,它的某种医疗作用还未被 FDA所确认,因此C是正确答案。A的内容不正确,因为它指的是被文明规定禁止的用途。B的内容是错误的,unlabeled use指的是当初该药品被批准使用时还未曾考虑到的用途,但是在以后的使用过程中被发现了,事后因时间关系未曾被官方提出过,也未曾测试过,也未曾否定过。D的内容也是错误的,如果是这样的话,作者一定会认为这是labeled use。
转载请注明原文地址:https://tihaiku.com/zcyy/3892273.html
相关试题推荐
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonlyf
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Underexistinglaw,anewdrugmaybelabeled,promoted,andadvertisedonly
Manyofthehomeelectricgoodswhichareadvertisedasliberatingthemode
随机试题
[originaltext]M:Ilikethecolorofthisshirt.Doyouhavealargersize?W:
电子显微镜下观察到转录过程的羽毛状图形说明()A.模板一直打开成单链 B
通过交谈收集资料的方法,错误的是A.让病人畅所欲言,切忌打断话题 B.告知交谈
Graves病病因是A.变应原引起的IgE介导的变态反应 B.IgM,Ig
在下列关于头肩顶底形态的表述中,正确的有()。A:头肩顶摩形态具有预测股份下跌或
苍术的主治病证不包括A.痰饮 B.夜盲 C.水肿 D.胎动不安 E.湿阻
某食品公司在2014年投保了产品责任保险,保险期限为一年,在保险期限内顾客食用该
代理人以被代理人的名义与自己进行民事法律行为,以下说法正确的有( )。A.其行为
经纬仪主要由()组成。A.三脚架、照准部和水平度盘 B.基座、照准部和三
依据《矿山安全法》的规定,矿山企业的()必须接受专门培训,经考核合格取得操作
最新回复
(
0
)